2012 OIG Roundtables on Corporate Integrity Agreements


In February and August 2012, the Office of Inspector General (“OIG”) of the Department of Health and Human Services (“HHS”) held roundtable discussions with compliance representatives from 32 companies that had entered into Corporate Integrity Agreements (“CIAs”) with the OIG since 2009. The discussions were designed to provide feedback to the OIG on practical implementation issues associated with CIA requirements. Both roundtables addressed challenges with CIA implementation and offered suggestions for improvement. The OIG summarized the discussions in two summary reports: Report from February 23, 2012, Pharmaceutical Compliance Roundtable, issued on March 26, 2012, and Focus on Compliance: The Next Generation of Corporate Integrity Agreements, issued on October 9, 2012. It also noted areas where companies expressed an intention to continue CIA-based practices even after their CIA expires. These references may be seen as an attempt by OIG to mold best practices for compliance programs industrywide.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Ropes & Gray LLP | Attorney Advertising

Written by:


Ropes & Gray LLP on:

Popular Topics
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.